Aerie Pharmaceuticals Inc. (NASDAQ:AERI) was up 2.3% on Monday . The company traded as high as $19.60 and last traded at $19.60, with a volume of 185,796 shares trading hands. The stock had previously closed at $19.15.

A number of equities research analysts have weighed in on AERI shares. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Brean Capital reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Monday, May 16th. Cantor Fitzgerald started coverage on shares of Aerie Pharmaceuticals in a research report on Thursday, June 2nd. They set a “buy” rating and a $44.00 price target for the company. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Tuesday, May 3rd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Aerie Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $42.50.

The firm’s market capitalization is $542.78 million. The firm’s 50-day moving average price is $17.97 and its 200 day moving average price is $16.09.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.02. On average, equities analysts expect that Aerie Pharmaceuticals Inc. will post ($2.74) EPS for the current fiscal year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. bought 250,000 shares of Aerie Pharmaceuticals stock in a transaction on Friday, July 22nd. The shares were bought at an average cost of $17.50 per share, for a total transaction of $4,375,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.